Skip to content

Exploration of intratumoral heterogeneity phenotypes, mechanisms, and treatment targets in liver cancer based on multiomics

Exploration of Intratumoral Heterogeneity Phenotypes, Mechanisms, and Treatment Targets in Liver Cancer Based on Multiomics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085207
Enrollment
Unknown
Registered
2024-06-03
Start date
2024-06-15
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Liver resection group:NA

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ?=18 years old. ? Patients diagnosed with primary liver cancer pathologically. ? The patient did not receive chemoradiotherapy, immunization and targeted therapy before surgery. ? Liver 3.0 MR enhancement and abdominal CT enhancement were completed within 1 month before surgery. ? Volunteer to participate in this study and sign the informed consent form. If the subject is unable to read and sign the informed consent form due to incapacity or other reasons, his or her guardian must represent the informed process and sign the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subject), a witness must witness the informed process and sign the informed consent form.

Exclusion criteria

Exclusion criteria: ? Patients with incomplete clinical data. ? Complicated with tumors in other locations. ? Family history of cancer. ? The quality of preoperative imaging data was poor. ? Vulnerable groups, including people with mental illness, people with cognitive impairment, critically ill patients, pregnant women, etc.

Design outcomes

Primary

MeasureTime frame
Postoperative patient survival;

Secondary

MeasureTime frame
Tumor markers;Blood routine;Coagulation function;Blood biochemistry;

Countries

China

Contacts

Public ContactXiao Liang

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

srrshlx@163.com+86 135 8870 8506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026